Immunohistochemistry-based assessment of androgen receptor status and the AR-null phenotype in metastatic castrate resistant prostate cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Immunohistochemistry-based assessment of androgen receptor status and the AR-null phenotype in metastatic castrate resistant prostate cancer

Published:2020-02-24 Issue:3 Volume:23 Page:507-516
ISSN:1365-7852
Container-title:Prostate Cancer and Prostatic Diseases
language:en
Short-container-title:Prostate Cancer Prostatic Dis

Author:

Gupta Sounak,Vanderbilt Chad,Abida Wassim,Fine Samson W.,Tickoo Satish K.,Al-Ahmadie Hikmat A.^ORCID,Chen Ying-Bei^ORCID,Sirintrapun Sahussapont J.,Chadalavada Kalyani,Nanjangud Gouri J.,Bialik Ann,Morris Michael J.^ORCID,Scher Howard I.,Ladanyi Marc,Reuter Victor E.,Gopalan Anuradha

Funder

U.S. Department of Health & Human Services | NIH | National Cancer Institute

United States Department of Defense | United States Army | Army Medical Command | Congressionally Directed Medical Research Programs

Prostate Cancer Biorepository Network-PCRP Pathology Resource Network Award

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Urology,Oncology

Link

http://www.nature.com/articles/s41391-020-0214-6.pdf

Reference34 articles.

1. Crawford ED, Higano CS, Shore ND, Hussain M, Petrylak DP. Treating patients with metastatic castration resistant prostate cancer: a comprehensive review of available therapies. J Urol. 2015;194:1537–47.

2. Wale DJ, Viglianti BL, Gross MD, Ferretti A, Rubello D, Wong KK. Nuclear medicine therapy with 223radium-dichloride for osseous metastases in prostate carcinoma. Am J Clin Oncol. 2019;42:99–106.

3. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl J Med. 2010;363:411–22.

4. Bluemn EG, Coleman IM, Lucas JM, Coleman RT, Hernandez-Lopez S, Tharakan R, et al. Androgen receptor pathway-independent prostate cancer is sustained through FGF signaling. Cancer Cell. 2017;32:474–89. e476.

5. Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K, et al. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate Cancer Clinical Trials Working Group 3. J Clin Oncol. 2016;34:1402–18.

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Single-cell analysis of treatment-resistant prostate cancer: Implications of cell state changes for cell surface antigen–targeted therapies;Proceedings of the National Academy of Sciences;2024-07-05

2. Single Cell Analysis of Treatment–Resistant Prostate Cancer: Implications of Cell State Changes for Cell Surface Antigen Targeted Therapies;2024-04-12

3. Genomic and Phenotypic Biomarkers for Precision Medicine Guidance in Advanced Prostate Cancer;Current Treatment Options in Oncology;2023-08-10

4. Reprint of: lessons from histopathologic examination of nephrectomy specimens in patients with tuberous sclerosis complex: cysts, angiomyolipomas & renal cell carcinoma;Human Pathology;2023-03

5. Lessons from histopathologic examination of nephrectomy specimens in patients with tuberous sclerosis complex: cysts, angiomyolipomas, and renal cell carcinoma;Human Pathology;2022-11

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3